Company

TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with an advanced clinical stage pipeline of adult stem cell programmes, and a commercialised product. The stem cell programmes are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory and heart diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency.

Cx601 is in Phase III to treat complex perianal fistulas in patients with Crohn’s disease. The product has met the primary endpoint of this trial at Week 24 of treatment which will allow for filing for European marketing authorisation in the first quarter of 2016. Cx611 has successfully concluded a Phase IIa trial in rheumatoid arthritis, and is now in development for early rheumatoid arthritis and for severe sepsis.

Effective as of July 31, 2015, TiGenix acquired Coretherapix, whose lead cardiac stem cell product (AlloCSC-01) is currently in a Phase II clinical trial in acute myocardial infarction (AMI). Additional planned projects are the clinical evaluation of AlloCSC-01 in the chronic setting, and the pre-clinical development of a pharmaceutical formulation of growth factors to treat AMI.

The company’s commercialised product, ChondroCelect®, for cartilage repair in the knee, was the first cell-based product approved in Europe, and is marketed and distributed by Swedish Orphan Biovitrum AB (‘Sobi’, NASDAQ OMX Stockholm: SOBI) and Finnish Red Cross Blood Service (FRCBS).

TiGenix is based in Leuven, Belgium, and has operations in Madrid , Spain.

Read more...

Products

Pipeline Update

Read more...

Latest News

3 May 2016 - Convening notice to the annual shareholders’ meeting to be held on 2 june 2016 (EN - NL)

12 April 2016 - TiGenix reports 2015 full year results (EN - NL - FR) - Webcast - Financial statement (EN)

25 March 2016 - Transparency Information (EN - NL)

22 March 2016 - TiGenix publishes transparency notifications pursuant to Article 14 of the Law of May 2, 2007 (EN - NL)

18 March 2016 - TiGenix: notice in relation to the convertible bonds due 2018 (EN - NL - FR)

Read more...

Company slide deck

2016 - Corporate Presentation

Management presentations

Full Year 2015 Business and Financial Update

ECCO Plenary ADMIRE-CD presentation

TiGenix ECCO Symposium presentations

Interview with De Tijd, 23 September 2015

Mediafin Investor Night (ENG - FR), 23 September 2015

HY15 results webcast presentation 15 September 2015

1H 2015 results webcast recording, September 2015

TiGenix Cx601 ADMIRE-CD Top-Line Results Webcast, August 2015

Tigenix at Alliance for Regenerative Medicine Conference, March 2015

TiGenix on Kanaal Z television, November 2014